NMDA Receptor Modulation in Treatment-Resistant Depression

Treatment-resistant depression presents a substantial clinical challenge, with patients failing to respond adequately to conventional antidepressants. Converging evidence implicates dysregulation of N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of refractory mood disorders. By modulating glutamatergic signalling, agents that antagonise or fine-tune NMDA receptor function can induce rapid and sustained antidepressant responses. Ketamine has pioneered this field, offering proof of principle for NMDA receptor blockade as a fast-acting intervention. More recent efforts have expanded beyond direct antagonism to target downstream effectors—such as calcium-sensitive potassium channels and neurotrophic signalling cascades—to enhance synaptic plasticity with fewer psychotomimetic side effects. Preclinical and early clinical work also suggests that NMDA receptor modulation may disrupt maladaptive memory reconsolidation, thereby attenuating negative cognitive biases that perpetuate depressive episodes. Collectively, these approaches underline the global significance of NMDA receptor modulation and lay the groundwork for innovative therapies capable of delivering rapid relief to those with treatment-resistant depression.

Research from Nature Portfolio

A study employing inhaled nitrous oxide revealed that its rapid antidepressant action arises not solely from NMDA receptor blockade but via inhibition of SK2 (small-conductance calcium-activated potassium) channels in layer V pyramidal neurons of the anterior cingulate cortex. In rodent models of chronic stress, a single subanaesthetic dose activated these neurons despite pharmacological or genetic attenuation of NMDA receptor function. This SK2-mediated excitation proved necessary for durable restoration of cortical activity and behavioural resilience, identifying a novel circuit-specific mechanism for fast-acting antidepressant effects.

NMDA Receptor Modulation in Treatment-Resistant Depression publication trend

The graph below shows the total number of articles in nmda receptor modulation in treatment-resistant depression across all publications each year (not limited to Nature Index journals).

Technical terms

NMDA receptor: An ionotropic glutamate receptor subtype critical for synaptic plasticity and memory formation, composed of multiple subunits that regulate calcium influx.

Treatment-resistant depression: A major depressive disorder variant unresponsive to at least two adequate trials of standard antidepressants.

SK2 channel: A small-conductance, calcium-activated potassium channel that modulates neuronal excitability downstream of NMDA receptor activity.

TrkB receptor: A receptor tyrosine kinase activated by brain-derived neurotrophic factor (BDNF), essential for synaptic growth and plasticity.

Reconsolidation: The process by which retrieved memories become labile and are restabilised, offering a window for targeted modification of maladaptive memory traces.

References

1. Nitrous oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect. Nature Communications (2025).
2. Examining memory reconsolidation as a mechanism of nitrous oxide’s antidepressant action. Neuropsychopharmacology (2025).
3. Nitrous oxide induces hypothermia and TrkB activation: Maintenance of body temperature abolishes antidepressant-like effects in mice. Neuropharmacology (2024).
4. Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Frontiers in Psychiatry (2015).